DoW Toxic Exposures Translational Research Award

<p><strong>Summary:</strong> The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan.<strong><em>&nbsp;</em></strong></p>

<p><br></p>

<p><strong>Distinctive Features:</strong><strong style="color: red;"> </strong>To encourage applications that include meaningful and productive collaborations, the FY26 TERP TRA includes a <strong>Partnering Principal Investigator Option (PPIO).</strong> One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI.<strong> </strong>If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising ideas into clinical applications.<strong> </strong>Partnering should significantly advance the research beyond what would be possible through individual efforts.</p>

<p><br></p>

<p><a href="https://cdmrp.health.mil/pubs/press/2026/terppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/terppreann</a></p>